CN105998578A - Liver-protecting composition - Google Patents
Liver-protecting composition Download PDFInfo
- Publication number
- CN105998578A CN105998578A CN201610578456.5A CN201610578456A CN105998578A CN 105998578 A CN105998578 A CN 105998578A CN 201610578456 A CN201610578456 A CN 201610578456A CN 105998578 A CN105998578 A CN 105998578A
- Authority
- CN
- China
- Prior art keywords
- liver
- fatty liver
- compositions
- bulbus allii
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/896—Liliaceae (Lily family), e.g. daylily, plantain lily, Hyacinth or narcissus
- A61K36/8962—Allium, e.g. garden onion, leek, garlic or chives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a liver-protecting composition and belongs to the field of medicine and healthcare. The composition is composed of the following components according to parts by weight: 20-45 parts of puerarin, 50-70 parts of garlic extract and 5-10 parts of soybean isoflavone; the composition of the invention has an effective rate of up to 100% for alcoholic fatty liver and an effective rate of higher than 95% for obesity fatty liver, has significant effect for inflammation-complicated stage-II fatty liver with an effective rate higher than 92% and has less irritation to stomach and intestines, a return visit 2 months after consumption of the composition shows that the ratio for gastrointestinal adverse response is reduced to less than 5% with no other side effects, the composition may be consumed often as a liver-protecting drug or health-care product and may effectively assist in treating severe type-II and even type-III fatty liver.
Description
Technical field
The present invention relates to medicines and health protection field, particularly relate to a kind of compositions for hepatoprotective.
Background technology
In the disease of hepar damnification, fatty liver is the second largest disease being only second to viral hepatitis, along with sending out of society
Exhibition and growth in the living standard, the sickness rate of fatty liver is more and more higher.For the classification of fatty liver, the most multiple most common master
If obese fatty liver, alcoholic fatty liver and diabetic fatty liver.
In order to prevent or treat above-mentioned fatty liver, those skilled in the art have carried out a lot of effort, and achieve certain
Progress.Such as liver-protecting tablet, glucuronolatone etc. are widely applied for a long time.The most such as, publication No. is the Chinese special of 102106876A
Profit application, discloses a kind of antialcoholism capsule containing Fructose Diphosphate sodium, puerarin and Ganoderma spore powder with cellular wall broken, this glue that relieves the effect of alcohol
There is cost of material height, complicated process of preparation and the problem of less effective in capsule.During the most such as publication No. is CN101874857A
State's patent application, discloses a kind of liver-protecting white spirit containing Radix Puerariae, Fructus Lycii, Fructus Crataegi and Fructus Chaenomelis, and this liver-protecting white spirit exists raw material
The more more complicated and problem of less effective.In addition, also has a lot of combination using Radix Puerariae or puerarin to carry out compatibility
The report of thing, they also tend to exist, and raw material is more, be difficult to acquisition, the asking of complex manufacturing technology, relatively costly, less effective
Topic.Owing to all of medicine is as ethanol, it is typically necessary and carries out metabolism through liver, if composition is the most complicated, on the contrary
The burden of liver can be increased so that the effect of relieving alcoholism and protecting the liver is had a greatly reduced quality, and the most multicomponent pharmacology is the clearest, especially
Interacting after compatibility is the most indefinite for healthy impact, there is potential danger.
The Chinese Patent Application No. 201310157072.2 of present inventor, patent name one relieving alcoholism and protecting the liver combine
Thing and application thereof, disclose the compositions using puerarin and Bulbus Allii as relieving alcoholism and protecting the liver, and said composition is only for Alcoholic fat
Fat liver effect is notable, and the effect for obese fatty liver is the most notable;And, said composition is not for accompanying I phase fat of inflammation
Fat liver effect is notable, but for the II phase fatty liver with inflammation, effect is not notable, it addition, long-term taking, to gastrointestinal tract also
Producing certain zest, after taking 1 month, the patient feedback that there are about 20% has gastrointestinal side effect.
Summary of the invention
One of goal of the invention of the present invention, is to provide the compositions for hepatoprotective of a kind of improvement, to solve above-mentioned depositing
Problem.
The technical solution used in the present invention is such that a kind of compositions for hepatoprotective, by following components in parts by weight
Composition:
Puerarin 20-45 part
Bulbus Allii extract 50-70 part
Soybean isoflavone 5-10 part.
Above-mentioned weight ratio is dry weight, and in each component, biodiversity content is below 1%.
Radix Puerariae (Radix Puerariae) is legume pueraria lobata, for the plant of a kind of common medicine-food two-purpose.Modern medicine
Pharmacological research shows, Radix Puerariae has the hepatocellular regeneration capacity of raising, recovers normal liver function, promotes bile secretion, prevents
Fat is piled up at liver, and can enhance metabolism, and strengthens liver detoxification function, prevents the ethanol effect to the damage of liver,
Flavones ingredient puerarin (puerarin) therein has played Main Function especially, and then people are applied to relieving alcoholism and protecting the liver
Medicine or health product, but its less effective, particularly with fatty liver;
Bulbus Allii (Allium sativum L) is Liliaceae allium, its underground bulb conventional.Garlicin therein has had
Report can be used for relieving the effect of alcohol, but its effect needs to be improved further, and similarly for the less effective of fatty liver;
Soybean isoflavone (CatheRine Genistein), is the class secondary metabolite formed in Semen sojae atricolor growth, delays female
Property old and feeble, improve menopause syndrome, osteoporosis, blood fat rising, breast carcinoma, carcinoma of prostate, heart disease, osteoporosis, cardiovascular
Disease etc..Person horizontal for high estrogen, shows as antihormonal activity, can prevent and treat mammary gland, endometrium, colon, prostate,
The growth of the cancerous cell such as lung, skin and leukemia, and other cardiovascular disease.The preferred Semen sojae atricolor of soybean isoflavone of the present invention
(Glycinemax(L.) merr) in soybean isoflavone, from Semen sojae atricolor extract soybean isoflavone be known in the art technology;
Inventor is found by great many of experiments: on the basis of puerarin and Bulbus Allii, adds appropriate soybean isoflavone, can improve
Only contain only the compositions of puerarin and Bulbus Allii for obese fatty liver and with the II phase fatty liver less effective of inflammation
Situation, three constituents are mutually coordinated, create beyond thought effect.
As preferred technical scheme, it is made up of following components in parts by weight
Puerarin 20-45 part
Bulbus Allii extract 50-70 part
Soybean isoflavone 5-10 part
Vitamin C 2-5 part.
Vitamin C, is also called ascorbic acid, is formed for antibody and collagen, and tissue repairing (includes that some oxidoreduction is made
With), phenylalanine, tyrosine, the metabolism of folic acid, ferrum, the utilization of carbohydrate, fat, the synthesis of protein, maintain immunity
Function, hydroxylation and hydroxytryptamine, keep the complete of blood vessel, promote that the institutes such as nonheme iron absorption are required, vitamin C is also equipped with simultaneously
There are antioxidation, free radical resisting, the formation of suppression tryrosinase, thus reach whitening, effect of light speckle.
Adding appropriate vitamin C on the basis of aforementioned three constituents, its effect further enhances, and side effect simultaneously is entered
One step reduces.
As preferred technical scheme, described Bulbus Allii extract is Bulbus Allii ethanol-water solution extract.
Further study showed that: raw material Bulbus Allii is extracted by ethanol-water solution, other useless one-tenth in removing Bulbus Allii
Point, refined effective ingredient therein so that hepatoprotective effect more precisely, also further mitigates the metabolism burden of liver, enhances
The metabolic function of liver.
Extracting method is: after being smashed to pieces by Bulbus Allii, adds aquiferous ethanol and soaks, and can be aided with ultrasonic acceleration and extract, simultaneously
Can be aided with heating, but heating-up temperature should not be higher than 60 DEG C, in order to improve extraction efficiency, extraction time can control at 2 hours,
Then filter, concentrate, be dried, to obtain final product.
As preferred technical scheme: described ethanol-water solution is percent by volume ethanol: water=60%-65%:35%-
40%。
The application, on the basis of patent before, further improves and extracts the concentration of alcohol of effective ingredient in Bulbus Allii, make
While hepatoprotective effect further enhances, reduce further side effect.
The two of the purpose of the present invention, are to provide a kind of combinations of the above thing to cause for preventing or treating ethanol in preparation
Hepatic injury medicine in application.
The three of the purpose of the present invention, are to provide a kind of combinations of the above thing in preparation for preventing or treating fatty liver
Application in medicine.
As preferred technical scheme: add pharmaceutically acceptable adjuvant and make capsule.
As preferred technical scheme: add pharmaceutically acceptable adjuvant and make tablet.
In sum, owing to have employed technique scheme, the invention has the beneficial effects as follows: the compositions of the present invention for
The effective percentage of alcoholic fatty liver reaches 100%, and the effective percentage for obese fatty liver reaches more than 95%, simultaneously for companion
The II phase fatty liver effect having inflammation is notable, and effective percentage can reach more than 92%, reduces simultaneously for gastrointestinal zest,
Pay a return visit after taking 2 months, the ratio near less than 5% of gastrointestinal side effect occurs, also has no other side effect, can conduct
Liver-protecting medicine or health product long-term taking, it is possible to controlling of the II type even III type fatty liver that effectively auxiliary is the most serious
Treat.
Detailed description of the invention
Below in conjunction with embodiment, the present invention is described in detail.
In order to make the purpose of the present invention, technical scheme and advantage clearer, below in conjunction with embodiment, to the present invention
It is further elaborated.Should be appreciated that specific embodiment described herein, only in order to explain the present invention, is not used to
Limit the present invention.
Embodiment 1:
A kind of compositions for hepatoprotective, is made up of the component of following weight:
Puerarin 20g
Bulbus Allii extracts 70g
Soybean isoflavone 10g
After above-mentioned composition mix homogeneously, make capsule 100.
Wherein, the preparation method of Bulbus Allii extract is: after being smashed to pieces by Bulbus Allii, adds aquiferous ethanol (ethanol and the volume of water
Ratio is 65:35) soak, and it is aided with ultrasonic acceleration extraction, and it is aided with 50 DEG C of heating, extraction time controls at 2 hours, then
Filter, concentrate, vacuum drying, to obtain final product.
Vitamin C 2-5 part.
Embodiment 2:
A kind of compositions for hepatoprotective, is made up of the component of following weight:
Puerarin 45g
Bulbus Allii extracts 50g
Soybean isoflavone 5g
After above-mentioned composition mix homogeneously, make capsule 100.
Wherein, the preparation method of Bulbus Allii extract is: after being smashed to pieces by Bulbus Allii, adds aquiferous ethanol (ethanol and the volume of water
Ratio is 60:40) soak, and it is aided with ultrasonic acceleration extraction, and it is aided with 50 DEG C of heating, extraction time controls at 2 hours, then
Filter, concentrate, vacuum drying, to obtain final product.
Embodiment 3:
A kind of compositions for hepatoprotective, is made up of the component of following weight:
Puerarin 30g
Bulbus Allii extracts 62g
Soybean isoflavone 8g
After above-mentioned composition mix homogeneously, make capsule 100.
Wherein, the preparation method of Bulbus Allii extract is: after being smashed to pieces by Bulbus Allii, adds aquiferous ethanol (ethanol and the volume of water
Ratio is 65:35) soak, and it is aided with ultrasonic acceleration extraction, and it is aided with 50 DEG C of heating, extraction time controls at 2 hours, then
Filter, concentrate, vacuum drying, to obtain final product.
Embodiment 4:
A kind of compositions for hepatoprotective, is made up of the component of following weight:
Puerarin 30g
Bulbus Allii extracts 62g
Soybean isoflavone 8g
Vitamin C 3g
After above-mentioned composition mix homogeneously, make capsule 100.
Wherein, the preparation method of Bulbus Allii extract is: after being smashed to pieces by Bulbus Allii, adds aquiferous ethanol (ethanol and the volume of water
Ratio is 65:35) soak, and it is aided with ultrasonic acceleration extraction, and it is aided with 50 DEG C of heating, extraction time controls at 2 hours, then
Filter, concentrate, vacuum drying, to obtain final product.
Embodiment 5 mice relieving alcoholic intoxication is tested
This test still uses the embodiment 1 of the embodiment part of the Chinese patent application of Publication No. 102727571A to record
Test method, wherein
Test specimen includes: experimental group 1-4(is respectively the relieving alcoholism and protecting the liver compositions obtained by the embodiment of the present application 1-4);Test
(wherein " matched group 1 " is the combination obtained by Chinese patent embodiment 6 of Chinese Patent Application No. 201310157072.2 in comparison
Thing, " matched group 2 " is the Medicament for Alcoholism comprising only soybean isoflavone, and " matched group 3 " is for comprising only vitamin C);
Subjects: the Red Star strong, colourless liquor distilled from sorghum of 56 °, Hongxing Co., Ltd. Beijing;SPF level male mice 210, body weight 20 ±
2g;
Test method: (1-4 group difference compositions obtained by gavage the embodiment of the present application 1-4, the 5th group is to be randomly divided into 7 groups
Aforesaid " matched group 1 ", the 6th group is aforesaid " matched group 2 ", and the 7th group is aforesaid " matched group 3 ") often organize 30, every is little
The groundwater increment of Mus test specimen is 0.2mg/10g body weight by dry weight, and remaining is special with the China of Publication No. 102727571A
The test method that the embodiment 1 of the embodiment part of profit application is recorded is the same, the tolerance time that obtains and holding time as in table 1
Shown in:
Table 1 mice relieving alcoholic intoxication result of the test: (unit of time is min)
Group | Tolerance time | Hold time | Group | Tolerance time | Hold time |
1 | 72.9±21.2 | 162.0±22.0 | 5 | 71.1±19.1 | 165.9±22.3 |
2 | 73.4±21.5 | 161.5±21.9 | 6 | 21.3±9.3 | 339.2±60.7 |
3 | 79.2±22.9 | 159.3±23.2 | 7 | 16.9±9.1 | 351.5±69.7 |
4 | 79.3±22.9 | 159.7±23.1 |
As it can be seen from table 1 the compositions that the application prepares, there is excellent dispelling effects of alcohol.
The loss test of embodiment 6 anti-acute alcohol liver
Test specimen is as the above embodiments 5, and subjects is SPF level male alcoholic hepatic injury mice 210, body weight 20
± 2g, is randomly divided into 7 groups, and wherein 1-4 group is administered the compositions of the embodiment of the present application 1-4 respectively, and the 5th group is aforesaid " right
According to group 1 ", the 6th group is aforesaid " matched group 2 ", and the 7th group is aforesaid " matched group 3 ") often organize 30, every mouse test sample
The groundwater increment of product is 0.2mg/10g body weight by dry weight, and remaining test method is special with the China of Publication No. 102727571A
The test method that the embodiment 3 of the embodiment part of profit application is recorded is consistent, and testing program difference therein is: every little
The dosage of Mus test specimen every day all by the standard of 600mg/kg bw, mice serum ALT, the AST finally recorded activity,
CHOL and TG content is as shown in table 2, and in the murine liver tissue recorded, SOD, GSH activity and MDA content are as shown in table 3;
Table 2 mice serum ALT, AST activity, CHOL and TG content, wherein CHOL unit is (mg/dL), and TG unit is (mmol/
L)
Group | AST/ALT | CHOL | TG | Group | AST/ALT | CHOL | TG |
1 | 2.70±0.32 | 1.82±0.27 | 0.692±0.12 | 5 | 2.71±0.33 | 1.85±0.27 | 0.62±0.15 |
2 | 2.69±0.35 | 1.81±0.26 | 0.61±0.12 | 6 | 3.51±0.45 | 2.61±0.39 | 0.99±0.65 |
3 | 2.63±0.25 | 1.79±0.26 | 0.60±0.11 | 7 | 3.65±0.55 | 2.79±0.47 | 1.23±0.72 |
4 | 2.63±0.24 | 1.79±0.25 | 0.59±0.11 |
SOD, GSH activity and MDA content in table 3 murine liver tissue, wherein SOD unit is (U/mg pro), and GSH unit is
(mg/g pro), MDA unit is (n mol/mg pro)
Group | SOD | GSH | MDA | Group | SOD | GSH | MDA |
1 | 170.8±18.3 | 313.3±45.7 | 9.2±2.1 | 5 | 176.8±16.5 | 308.2±45.9 | 9.8±1.9 |
2 | 175.6±17.1 | 311.5±45.9 | 9.1±2.1 | 6 | 136.2±25.3 | 232.2±47.2 | 17.3±2.5 |
3 | 185.9±18.1 | 327.8±45.9 | 8.7±1.8 | 7 | 132.5±24.3 | 229.6±68.7 | 19.1±6.5 |
4 | 186.8±17.1 | 329.2±46.6 | 8.9±1.8 |
From table 2, table 3 it can be seen that the compositions for preparing of the application, the effect in terms of hepatoprotective, it is markedly improved.
Embodiment 7 is for the clinical trial of obese type fatty liver
Choose 150 volunteers, these 150 through clinical examination, intrahepatic fat weight is between the 8%-10% of liver weight, and body
Weight average exceeds standard about 20%, is randomly divided into 3 groups, often organizes 50 people and take the embodiment of the present invention 3, embodiment 4 and Chinese patent Shen respectively
Please numbers 201310157072.2 the compositions (" contrast groups ") of Chinese patent embodiment 6, Time of Administration is 2 months, then examines
Looking into, intrahepatic fat content reduces by more than 1% for " effective ", intrahepatic fat content but be higher than 5% within being down to 5% is " effectively ", its system
Meter the results are shown in Table 4
Table 4 is for the clinical test results (unit: people) of obese type fatty liver
Group | Effective | Effectively |
Embodiment 3 | 32 | 18 |
Embodiment 4 | 35 | 15 |
Contrast groups | 9 | 23 |
Embodiment 8 is for the clinical trial of the II phase fatty liver with inflammation
Choose 150 volunteers, these 150 through clinical examination, with II phase fatty liver of inflammation, all different journey of its transaminase
Degree raises, and intrahepatic fat weight is between the 8%-10% of liver weight, is randomly divided into 3 groups, often organizes 50 people and takes the present invention respectively in fact
Execute the compositions (" contrast of the Chinese patent embodiment 6 of example 3, embodiment 4 and Chinese Patent Application No. 201310157072.2
Group "), Time of Administration is 2 months, then checks, within intrahepatic fat content near 5% and transaminase becomes normal for " aobvious
Effect ", intrahepatic fat content reduce by more than 1% but higher than 5% and transaminase be reduced to " effectively " in various degree, its statistical result is shown in
Table 4
Table 4 is for the clinical test results (unit: people) of obese type fatty liver
Group | Effective | Effectively |
Embodiment 3 | 27 | 23 |
Embodiment 4 | 29 | 21 |
Contrast groups | 6 | 21 |
The foregoing is only presently preferred embodiments of the present invention, not in order to limit the present invention, all essences in the present invention
Any amendment, equivalent and the improvement etc. made within god and principle, should be included within the scope of the present invention.
Claims (8)
1. the compositions for hepatoprotective, it is characterised in that be made up of following components in parts by weight:
Puerarin 20-45 part
Bulbus Allii extract 50-70 part
Soybean isoflavone 5-10 part.
2. the compositions for hepatoprotective, it is characterised in that be made up of following components in parts by weight
Puerarin 20-45 part
Bulbus Allii extract 50-70 part
Soybean isoflavone 5-10 part
Vitamin C 2-5 part.
3. the compositions for hepatoprotective as claimed in claim 1 or 2, it is characterised in that: described Bulbus Allii extract is Bulbus Allii
Ethanol-water solution extract.
4. the compositions for hepatoprotective as claimed in claim 1 or 2, it is characterised in that: described ethanol-water solution is volume
Percentage of ethanol: water=60%-65%:35%-40%.
5. the compositions described in claim 1 is preparing answering in the medicine of the hepatic injury preventing or treating ethanol to cause
With.
6. the compositions described in claim 2 is used for the application preventing or treating in the medicine of fatty liver in preparation.
7. the application as described in claim 5 or 6, it is characterised in that: add pharmaceutically acceptable adjuvant and make capsule.
8. the application as described in claim 5 or 6, it is characterised in that: add pharmaceutically acceptable adjuvant and make tablet.
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610667911.9A CN106038951A (en) | 2016-07-22 | 2016-07-22 | Liver-protecting capsules |
CN201610667845.5A CN106138653A (en) | 2016-07-22 | 2016-07-22 | A kind of liver-protecting tablet |
CN201610578456.5A CN105998578A (en) | 2016-07-22 | 2016-07-22 | Liver-protecting composition |
CN201610667874.1A CN106109873A (en) | 2016-07-22 | 2016-07-22 | Liver-protecting combination is used for the application preventing or treating in the medicine of fatty liver in preparation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610578456.5A CN105998578A (en) | 2016-07-22 | 2016-07-22 | Liver-protecting composition |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610667845.5A Division CN106138653A (en) | 2016-07-22 | 2016-07-22 | A kind of liver-protecting tablet |
CN201610667874.1A Division CN106109873A (en) | 2016-07-22 | 2016-07-22 | Liver-protecting combination is used for the application preventing or treating in the medicine of fatty liver in preparation |
CN201610667911.9A Division CN106038951A (en) | 2016-07-22 | 2016-07-22 | Liver-protecting capsules |
Publications (1)
Publication Number | Publication Date |
---|---|
CN105998578A true CN105998578A (en) | 2016-10-12 |
Family
ID=57117093
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610578456.5A Pending CN105998578A (en) | 2016-07-22 | 2016-07-22 | Liver-protecting composition |
CN201610667845.5A Pending CN106138653A (en) | 2016-07-22 | 2016-07-22 | A kind of liver-protecting tablet |
CN201610667911.9A Pending CN106038951A (en) | 2016-07-22 | 2016-07-22 | Liver-protecting capsules |
CN201610667874.1A Pending CN106109873A (en) | 2016-07-22 | 2016-07-22 | Liver-protecting combination is used for the application preventing or treating in the medicine of fatty liver in preparation |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610667845.5A Pending CN106138653A (en) | 2016-07-22 | 2016-07-22 | A kind of liver-protecting tablet |
CN201610667911.9A Pending CN106038951A (en) | 2016-07-22 | 2016-07-22 | Liver-protecting capsules |
CN201610667874.1A Pending CN106109873A (en) | 2016-07-22 | 2016-07-22 | Liver-protecting combination is used for the application preventing or treating in the medicine of fatty liver in preparation |
Country Status (1)
Country | Link |
---|---|
CN (4) | CN105998578A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108095125A (en) * | 2017-12-12 | 2018-06-01 | 浙江海洋大学 | A kind of brown croaker air bladder polypeptide health care food of liver protecting and preparation method thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103211957A (en) * | 2013-05-02 | 2013-07-24 | 赵月 | Alcohol relieving and liver protecting composition and application thereof |
CN103386075A (en) * | 2012-05-07 | 2013-11-13 | 宋凯 | Lozenge for sobering up and protecting liver |
-
2016
- 2016-07-22 CN CN201610578456.5A patent/CN105998578A/en active Pending
- 2016-07-22 CN CN201610667845.5A patent/CN106138653A/en active Pending
- 2016-07-22 CN CN201610667911.9A patent/CN106038951A/en active Pending
- 2016-07-22 CN CN201610667874.1A patent/CN106109873A/en active Pending
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103386075A (en) * | 2012-05-07 | 2013-11-13 | 宋凯 | Lozenge for sobering up and protecting liver |
CN103211957A (en) * | 2013-05-02 | 2013-07-24 | 赵月 | Alcohol relieving and liver protecting composition and application thereof |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108095125A (en) * | 2017-12-12 | 2018-06-01 | 浙江海洋大学 | A kind of brown croaker air bladder polypeptide health care food of liver protecting and preparation method thereof |
CN108095125B (en) * | 2017-12-12 | 2021-05-18 | 浙江海洋大学 | Liver-protecting miichthys miiuy swim bladder polypeptide health food and preparation method thereof |
Also Published As
Publication number | Publication date |
---|---|
CN106138653A (en) | 2016-11-23 |
CN106038951A (en) | 2016-10-26 |
CN106109873A (en) | 2016-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN100366280C (en) | Medicinal composition for treating hypertension, its preparation method and use | |
JP2007008965A (en) | Hair growing agent | |
CN1899342A (en) | Oral medicine for treating diabetes and its use | |
CN104857154A (en) | Traditional Chinese medicine composition for treating three-high diseases and preparation method therefor | |
CN103211957B (en) | Alcohol relieving and liver protecting composition and application thereof | |
CN103301267A (en) | Traditional Chinese medicine composition for treating hypertension and/or atherosclerosis and application thereof | |
CN1558768A (en) | A pharmaceutical composition made from Chinese traditional medicine and preparation method thereof | |
CN102846879B (en) | Composition for depressing blood fat | |
CN105998578A (en) | Liver-protecting composition | |
CN102895387B (en) | Kidney-yang-warming medicine composition, and preparation thereof and preparation method thereof | |
JP7340113B2 (en) | Chinese herbal composition and its production method and use | |
CN101244122A (en) | Pharmaceutical combination | |
CN107343925B (en) | Traditional Chinese medicine composition for treating chronic heart failure and preparation method thereof | |
CN108143800B (en) | Traditional Chinese medicine composition for treating hypertensive heart failure | |
CN1115159C (en) | Red sage containing medicine composition and its preparation and use | |
CN100464773C (en) | Yixinshu Injecta for retaliation of Qi and pulse and promotion of blood circulation and removing of blood stasis, and preparing method therefor | |
CN100574799C (en) | Radix Ginseng cold limbs injection and preparation method | |
CN104587300A (en) | Traditional Chinese medicine composition for treating acute leukemia and preparation method of traditional Chinese medicine composition | |
CN103920023A (en) | Traditional Chinese medicine for treating hypertension | |
CN104288566A (en) | Traditional Chinese medicine composition for reducing cholesterol and/or reducing blood lipids as well as preparation method and application of traditional Chinese medicine composition | |
CN104510857B (en) | A kind of Chinese medicinal effective-part composition for blood fat reducing and preparation thereof | |
CN101352488B (en) | Medicament composition for damp-heat type icterohepatitis and preparation method thereof | |
CN103110675A (en) | Soft capsule for improving alimentary anemia and preparation method thereof | |
CN101167796B (en) | Monascus and red sage root composition for preventing and treating cardiovascular and cerebrovascular diseases | |
CN106361829A (en) | Traditional Chinese medicine composition for treating ischemic stroke, preparation and preparation method thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20161012 |
|
RJ01 | Rejection of invention patent application after publication |